ENDOVENOUS LASER ABLATION OF THE GREAT SAPHENOUS VEIN IN PATIENTS WITH VON WILLEBRAND DISEASE (CASE REPORT)
Abstract
ABSTRACT
Introduction
In patients with von Willebrand's disease there is high risk of bleeding in surgical treatment of varicose veins. Endovenous laser ablation (EVLA) of the great saphenous vein (GSV) is minimally invasive treatment of saphenofemoral junction incompetence. Number of complications and relapse is smaller if compared to conventional surgical treatment.
Case presentation
A patient with great saphenous vein insufficiency, von Willbrand disease and hypofibrinogenemia successfully underwent endovenous laser ablation. Replacement therapy with cryoprecipitate was administered preoperatively and postoperatively. Surgical procedure and postoperative course were regular.
Conclusion
In patients with von Willebrand disease and other coagulation disorders, endovenous laser ablation is a safe and effective treatment. By using minimally invasive treatment, adequate correction of hemostasis, and close cooperation between hematologist, anesthesiologist and endovascular surgeon the risk of bleeding is reduced.
Key words: Von Willebrand disease; varicose veins; surgery; endovenous laser ablation; great saphenous vein;
References
Kreuz W. von Wilebrand‘s disease: from discovery to therapy - milestones in the last 25 years. Haemophilia. 2008;14(5): 1-2.
Federici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. Semin Thromb Hemost. 2006 Sep;32(6):555-65.
Ginsburg D, Wagner DD. Structure, biology and genetics of von Willebrand factor.In:Hofman of Hematology, Basic Princips and Practice, Elsevier Churchill Livingstone. 5th ed. 2008;1953- 59.
Grabowski EF, Curran MA, Van Cott EM. Assessment of a cohort of primary pediatric patients with presumptive diagnosis of type 1 von Willebrand disease with a novel high shear rate, non- citrated blood flow device.Thromb Res. Apr 2012;129(4): e- 18-24.
Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease. a report of the Subcommettee on von Willebrand factor. J Throm Haem 2006;4:2103-14.
Rick ME, Walsh CE, Key NS. Congenital bleeding disorders. Hematology Am Soc Hematol Educ Program 2003;559- 74.
Ginsburg D, Wagner DD. Structure, biology and genetics of von Willebrand factor.In: Hofman et al. Hematology, Basic principles and Practice , Elsevier Churchill Livingstone. 4th ed. 2005;1937- 58.
Sadler EJ. Von Willebrand disease type I: a diagnosis in search of disease .Blood 2003;101(6): 2089-93.
Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987 Feb; 69(2):454-9.
Franchini M. Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage. Blood Transfus. 2008 Sep;6 Suppl 2:s33-8.
Castaman G, Federici AB, Rodeghiero F, et al. Review Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.Haematologica. 2003 Jan; 88(1):94-108.
Franchini M, Targher G, Lippi G . Review Prophylaxis in von Willebrand disease. Ann Hematol. 2007 Oct; 86(10):699-704.
Federici AB, Baudo F, Caracciolo C, et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia. 2002;8:761–7.
Mannucci PM, Chediak J, Hanna W, et al. The Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002;99:450–6.
Franchini M, Rossetti G, Tagliaferri A, et al. Efficacy and safety of factor VIII/von
Thompson AR, Gill JC, Ewenstein BM, et al. Humate-P Study Group. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/von Willebrand factor concentrate (Humate-P) Haemophilia. 2004;10:42–51.
Bernstein J, Cox Gill J, Leissinger CA, et al. Humate P Study Group. Safety and efficacy of von Willebrand factor/factor VIII concentrate (Humate-P) for prophylaxis of excessive bleeding during elective surgery un patients with von Willebrand disease. Blood. 2006;108 abstract 4076.
Federici AB, Castaman G, Franchini M, et al. Clinical use of Haemate P in inherited von Willebrand disease: a cohort study on 100 Italian patients. Haematologica. 2007;92:944–51.
Lethagen S, Kyrle PA, Castaman G, et al. The Haemate P Surgical Study Group. Von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost. 2007; 5:1420–30.
Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost. 2007;5:1115–24.
Chastanet S, Pittaluga P. Patterns of reflux in the great saphenous vein system. Phlebology. 2013;28 Suppl 1:39-46. doi: 10.1177/0268355513477021.
Eklöf B, Rutherford RB, Bergan JJ et al. American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification.Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004 Dec;40(6):1248-52.
Carradice D, Mekako AI, Mazari FA, et al. Clinical and technical outcomes from a randomized clinical trial of endovenous laser ablation compared with conventional surgery for great saphenous varicose veins. Br J Surg. 2011 Aug;98(8):1117-23. doi: 10.1002/bjs.7615. Epub 2011 Jun 3.
Firouznia K, Ghanaati H, Hedayati M, et al Endovenous laser treatment (EVLT) for the saphenous reflux and varicose veins: a follow-up study. J Med Imaging Radiat Oncol. 2013 Feb;57(1):15-20. doi: 10.1111/j.1754-9485.2012.02457.x. Epub 2012 Oct 9.
Fischer R, Linde N, Duff C, et al. Late recurrent saphenofemoral junction reflux after ligation and stripping of the greater saphenous vein. J Vasc Surg 2001; 34: 236-240.
Chen JQ, Xie H, Deng HY, et al. Endovenous laser ablation of great saphenous vein with ultrasound-guided perivenous tumescence: early and midterm results. Chin Med J (Engl). 2013 Feb;126(3):421-5.
Zafarghandi MR, Akhlaghpour S, Mohammadi H, et al. Endovenous laser ablation (EVLA) in patients with varicose great saphenous vein (GSV) and incompetent saphenofemoral junction (SFJ): an ambulatory single center experience. Vasc Endovascular Surg. 2009 Apr-May;43(2):178-84. doi: 10.1177/1538574408326182. Epub 2008 Dec 16.
Luebke T, Brunkwall J. Systematic review and meta-analysis of endovenous radiofrequency obliteration, endovenous laser therapy, and foam sclerotherapy for primary varicosis. J Cardiovasc Surg (Torino) 2008; 49: 213-233.
Van den Bos R, Arends L, Kockaert M, et al. Endovenous therapies of lower extremity varicosities: a meta-analysis. J Vasc Surg 2009; 49: 230-239.
Flessenkämper I, Hartmann M, Stenger D, et al. Endovenous laser ablation with and without high ligation compared with high ligation and stripping in the treatment of great saphenous varicose veins: initial results of a multicentre randomized controlled trial. Phlebology. 2013;28(1):16-23. doi: 10.1258/phleb.2011.011147. Epub 2012 Mar 26.
Rasmussen LH, Bjoern L, Lawaetz M, et al.Randomized trial comparing endovenous laser ablation of the great saphenous vein with high ligation and stripping in patients with varicose veins: short-term results. J Vasc Surg. 2007 Aug;46(2):308-15. Epub 2007 Jun 27.
Christenson JT, Gueddi S, Gemayel G, et al. Prospective randomized trial comparing endovenous laser ablation and surgery for treatment of primary great saphenous varicose veins with a 2-year follow-up. J Vasc Surg. 2010 Nov;52(5):1234-41. doi: 10.1016/j.jvs.2010.06.104.
Darwood RJ, Theivacumar N, Dellagrammaticas D, et al. Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins. Br J Surg. 2008 Mar;95(3):294-301. doi: 1